Tonix Pharmaceuticals
TNXP
24 hedge funds and large institutions have $2.24M invested in Tonix Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
26% more funds holding
Funds holding: 19 → 24 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
61% less capital invested
Capital invested by funds: $5.81M → $2.24M (-$3.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$606K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$99.1K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$81.9K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$45.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$260K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$237K |
| 4 |
ACM
Altium Capital Management
New York
|
-$218K |
| 5 |
Renaissance Technologies
New York
|
-$38.8K |
TNXP Hedge Fund Activity: Q1 2024 in Review
24 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q1 2024, worth a combined $2.24M — down 61% from $5.81M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TNXP positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, adding an estimated $606K. The largest seller was Armistice Capital, cutting an estimated $1.1M.
- 24 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q1 2024, up from 19 in Q4 2023.
- Funds reported $2.24M of Tonix Pharmaceuticals stock for Q1 2024, down 61% quarter-over-quarter.
- 7 funds opened new Tonix Pharmaceuticals positions in Q1 2024 and 2 closed out, a net change of +5 holders.
- The largest Tonix Pharmaceuticals buyer in Q1 2024 was Sabby Management, an estimated $606K added.
- The largest Tonix Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2024.